Table 2.

General and clinical information of the included studies

Authors	Year	Time of study, design	Country	No. of patients (lesions)	Inclusion of pretreated patients	Sex (M/F)	Median age (range)	CP-A%	ECOG	Viral etiology (HBV + HCV %)	Inclusion of vascular invasion patients	Median/mean longest diameter (range, cm)
Sun et al. [10]	2019	2011–2014, R	China	108 (108)	No	80/28	54 (37–77)	100%	0–1	89.8%	No	2.3 (0.7–4.9)
Parikh et al. [11]	2018	2004–2011, R	USA	32 (NA)	No	20/12	66 (72,71) IQR	NR	NR	NR	No	≤ 5.0
Jun et al. [22]	2018	2011–2016, R	Korea	85 (125)	Yes	65/20	Mean 62.6 ± 10	83.5%	NR	68.2%	No	2.23 ± 1.17
Jeong et al. [19]	2018	2012–2013, R	Korea	119 (139)	Yes	97/22	60 (36–90)	90.8%	0–2	87.4%	No	1.7 (≤ 6.0)
Su et al. [23]	2016	2009–2015, R	China	132 (175)	Yes	110/22	58 (30–88)	86.4%	NR	90.2% (HBV only)	No	3.0 (1.1–5.0)
Scorsetti et al. [8]	2015	2010–2014, P	Italy	43 (63)	Yes	31/12	Mean 72 (46–87)	53.5%	0–2	69.8%	Yes	(≤ 6.0)
Kimura et al. [24]	2015	2008–2013, R	Japan	65 (74)	Yes	44–21	73 (49–90)	86.2%	0–1	90.8%	No	1.6 (0.5–5.4)
Shiozawa et al. [12]	2015	2011–2014, R	Japan	35 (35)	No	24/11	Mean 75.1 (55–89)	80.0%	0–2	77.1%	NR	2.86 ± 1.15 (1.2–5.0)
Sanuki et al. [25]	2014	2005–2012, R	Japan	185 (185)	Yes	119/66	74 (40–89)	85.4%	NR	82.2%	Yes	2.4(0.8–5.0)
Yoon et al. [9]	2013	2007–2009, R	Korea	93 (103)	Yes	75/18	61 (42–86)	74.2%	NR	87.1%	No	2.0(≤ 6.0)
Kwon et al. [16]	2010	2004–2007, R	Korea	42 (NA)	Yes	32/10	Mean 60.1 ± 10.9	90.5%	0–1	85.7%	No	(≤ 6.0)a
Jun et al. [17]	2018	2011–2015, R	Korea	117 (136)	Yes	86/31	63 (38–85)	76.1%	NR	65.0%	No	2.1 (1.0–4.0)
Takeda et al. [26]	2016	2007–2012, P	Japan	90 (90)	Yes	58/32	73 (48–85)	91.1%	0–2	88.9%	Yes	2.3 (1.0–4.0)
Jung et al. [18]	2013	2007–2009, R	Korea	92 (NA)	Yes	74/18	61 (42–86)	73.9%	0–2	75.0% (HBV only)	No	(≤ 6.0)

R retrospective, P prospective, NR not reported, IQR interquartile range;

^aDiameter is roughly calculated from volume, assuming tumor is spherical